Skip to main content
SpringerLink
Log in

Recent Advances in the Treatment of Gastric Cancer

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Gastric cancer is one of the most common cancers in the world. The prognosis of the disease is poor, with only 40% of patients eligible to undergo potentially curative surgery. Even for those patients who undergo a complete resection, the rate of recurrence is very high. Extensive studies of multidisciplinary adjuvant treatment have been conducted seeking to improve the cure rates in the past two decades. The benefit of D2 dissection is still controversial and is undergoing prospective evaluation. Preliminary results from the United States Gastrointestinal Intergroup study, a well designed trial, have shown overall survival benefit of postoperative chemoradiation therapy. Neoadjuvant chemotherapy or chemoradiation is under active study in order to increase the number of patients to undergo potential curative surgery. Although many chemotherapy regimens have been developed recently, only modest clinical efficacy has been demonstrated for advanced metastatic disease. So far, there is no single regimen considered to be standard.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brennan MF, Karpeh MS. Surgery for gastric cancer: the American View. Semin Oncol 1996; 23(3): 352–9

    PubMed  CAS  Google Scholar 

  2. Sasako M. What is reasonable treatment for gastric adenocarcinoma? J Gastricoenterol 2000; 35 Suppl. 12: 116–20

    Google Scholar 

  3. Bonenkamp JJ, Songun I, Hermans J, et al. Randomized comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345(8952): 745–8

    Article  PubMed  CAS  Google Scholar 

  4. Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat Rev 2000; 26(4): 243–55

    Article  PubMed  CAS  Google Scholar 

  5. Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary result of the MRC randomised controlled surgical trial: the Surgical Cooperative Group. Lancet 1996; 347(9007): 995–9

    Article  PubMed  CAS  Google Scholar 

  6. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymphnode disection for gastric cancer. N Engl J Med 1999; 340(12): 908–14

    Article  PubMed  CAS  Google Scholar 

  7. Cuschieri A, Weeden S, Fielding J, et al. Patients survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer 1999; 79(9-10): 1522–30

    Article  PubMed  CAS  Google Scholar 

  8. Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993; 11(8): 1441–7

    PubMed  CAS  Google Scholar 

  9. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomized trials. Eur J Cancer 1999; 35(7): 1059–64

    Article  PubMed  CAS  Google Scholar 

  10. Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomized trials. A study of the GISCAD. Ann Oncol 2000; 11(7): 837–43

    CAS  Google Scholar 

  11. Hallissey MT, Dunn JA, Ward LC, et al. The second British Stomach Cancer Group trial of adjuvant radiotherpy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994; 343(8909): 1309–12

    Article  PubMed  CAS  Google Scholar 

  12. Macdonald JS, Smalley S, Benedetti J, et al. Postoperation combination radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and G.E. junction. Results of inter-group study INT-0116 (SWOG 9008). Proc Am Soc Clin Oncol 2000, 19: la

    Google Scholar 

  13. Moertel CG, Childs DS, O’Fallon JR, et al. Combined 5-fluo-rouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 1984; 2: 1249–54

    PubMed  CAS  Google Scholar 

  14. Kelsen DP. Adjuvant and neoadjuvant therapy for gastric cancer. Semin Oncol 1996; 23(3): 379–489

    PubMed  CAS  Google Scholar 

  15. Lowy AM, Mansfield PF, Leach SD et al. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999; 229(3): 303–8

    Article  PubMed  CAS  Google Scholar 

  16. Stein HJ, Sendler A, Fink U, et al. Multidisplinary approach to esophageal and gastric cancer. Surg Clin North Am 2000; 80(2): 659–82

    Article  PubMed  CAS  Google Scholar 

  17. Mauer AM, Haraf DC, Ferguson MK et al. Docetaxel-based combined modality therapy for locally advance carcinoma of the esophagus and gastric carcinoma. Proc Am Soc Clin Oncol 2000; 19: A954

    Google Scholar 

  18. Potmesil M, Newman E, Yee H et al. Neoadjuvant therapy of gastric adenocarcinoma by CPT-11 (camptosar) and Cisplatin: preliminary surgical and histopathologic finding. Proc Am Clin Onocl 2000; 19: A1209

    Google Scholar 

  19. Mansfield PF, Lowy AM, Feig BW et al. Preoperative chemoradiation for potentially resectable gastric cancer. Proc Am Clin Oncol 2000; 19: A955

    Google Scholar 

  20. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubucin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261–7

    PubMed  CAS  Google Scholar 

  21. Cascinu S, Labianca R, Alessandroni P, et al. Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: Areport from the italian group for the study of digestive tract cancer. J Clin Oncol 1997; 15: 3313–9

    PubMed  CAS  Google Scholar 

  22. Eatock MM, Anthony DA, El-Abassi M, et al. A dose-finding study of raltetrexed (tomudex) with cisplatin and epirubicin in advanced gastr-oesophageal adenocarcinoma. Br J Cancer 2000; 82: 1925–31

    Article  PubMed  CAS  Google Scholar 

  23. Chi, KH, Chao Y, Chan WK, et al. Weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer. Br J Cancer 1998; 77: 1984–8

    Article  PubMed  CAS  Google Scholar 

  24. Water JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999; 80: 269–72

    Article  Google Scholar 

  25. Vanhoefer U, Rougier P, Wike H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracial and cisplatin in advanced gastric cancer: A trial of the European Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648–57

    PubMed  CAS  Google Scholar 

  26. Boku N, Ohsushi A, Shimada Y, et al. Phase JJ study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17: 319–23

    PubMed  CAS  Google Scholar 

  27. Bleiberg H. CPT-11 in gastrointestinal cancer. Eur J Cancer 1999; 35: 371–9

    Article  PubMed  CAS  Google Scholar 

  28. Blanke CD, Haller DG, Benson AB, et al. A multicenter phase II Study of CPT-11, 5-fluorouracil, and leucovorin (LCV) in patients with previous untreated adenocarcinoma of the stomach or GE junction. Proc Am Soc Clin Oncol 2000; 19: 292a (A1141)

    Google Scholar 

  29. Ajani JA, Fodor M, Cutsem EV, et al. Multinational randomized phase II trial of docetaxel (T) and cisplatin (C) with or without 5-fluorouracil (FU) in patients (pts) with advanced gastric or GE junction adenocacinoma (AGC-AGEJC). Proc Am Soc Clin Oncol 2000; 19: A957

    Google Scholar 

  30. Kollmannsberger C, Quietzsch D, Haag C, et al. Aphase II study of paclitaxel, weekly 24-hour continuous infusion (CI) 5-fluorouracil, folinic acid (FA) and cisplatin in patients (Pts) with advanced gastric cancer. Proc Am Clin Oncol. 2000; 19: A1030

    Google Scholar 

  31. Enzinger PC, Flson DM, Saltz LB, et al. Irinotecan and cisplatin in upper gastrointestinal malignacies. Oncology (Hamtingt) 1998; 12 (8 Suppl. 6): 110–3

    CAS  Google Scholar 

  32. Kretzschmar A, Reichardt P, Thuss-Patience PC, et al. Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mytomycin C for the treatment of advanced gastric cancer. Oncology 2000; 59(1): 14–7

    Article  PubMed  CAS  Google Scholar 

  33. Koizumi W, Tanabe S, Kurihara M, et al. Pilot study of combined treatment with continuous infusion of 5-fluorouracil, mytomycin C and cisplatin (FMP) in patients with inoperable advanced gastric cancer. Oncol Rep 1999; 6(3): 643–6

    PubMed  CAS  Google Scholar 

  34. Louvet C, Andre T, Tigaud J-T, et al. Phase II trial of oxalipatin (OXA) in combination with 5FU and folinic acid (FA)-FOLFOX6 regimen as first-line treatment for advanced or metastatic gastric cancer (A/MGC) patients. Proc Am Clin Oncol 2000; 19: A1031

    Google Scholar 

  35. Kroep JR, Peters GJ, Giaccone G, et al. Phase II study of cisplatin (CDDP) preceding gemcitabine (GEM) in patients with advanced gastric and esophageal cancer. Proc Am Clin Oncol 2000; 19: A1033

    Google Scholar 

  36. Eatock MM, Anthony DA, El-Abassi M, et al. A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma. Br J Cancer 2000; 82(12): 1925–31

    Article  PubMed  CAS  Google Scholar 

  37. Gonzalez Baron M, Espinosa E, Feliu J, et al. The UFT/leucovorin/etoposide regimen for the treatment of advanced gastric cancer. Oncopaz Cooperative Group. Oncology (Huntingt) 1997; 11 (9 Suppl. 10): 109–12

    Google Scholar 

  38. Sato A, Murihara M, Koizumi W, et al. Aphase II study of UFT plus cisplatin (UFTP therapy in patients with advanced gastric cancer. Proc Am Clin Oncol 2000; 19: A1087

    Google Scholar 

  39. Koizumi W, Kurihara M, Nakano S, et al. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 cooperative gastric cancer study group. Oncology 2000; 58(3): 191–7

    CAS  Google Scholar 

  40. Hagiwara A, Torii T, Sawai K, et al. Local injection of the anti-cancer drugs bound to carbon particles for early gastric cancer—a pilot study. Hepatogastroenterology 2000; 47(32): 575–8

    PubMed  CAS  Google Scholar 

  41. Imada T, Rino Y, Cyo H, et al. The detection of microscopicaaly disseminated cancer cells in the abdominal cavity by intraoperative lavage cytology combined with an immunocytochemical method in gastric cancer. Anticancer Res 1999; 19(6B): 4965–8

    PubMed  CAS  Google Scholar 

  42. Funami Y, Tokumoto N, Miyauchi H, et al. Prognostic value of peritoneal lavage cytology and chemotherapy during surgery for advanced gastric cancer. Int Surg 1999; 84(3): 220–4

    PubMed  CAS  Google Scholar 

  43. Weese JL, Harbison SP, Stiller GD, et al. Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): improved treatment for gastric adenocarcinoma. Surgery 2000; 128(4): 564–71

    Article  PubMed  CAS  Google Scholar 

  44. Samel S, Singal A, Becker H, et al. Problems with intraoperative hyperthermic peritoneal chemotherapy for advanced gastric cancer. Eur J Surg Oncol 2000; 26(3): 222–6

    Article  PubMed  CAS  Google Scholar 

  45. Hirose K, Katayama K, Lida A, et al. Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced grastric cancer: evaluation by multivariate regression analysis. Oncology 1999; 57(2): 106–14

    Article  PubMed  CAS  Google Scholar 

  46. Nabeya Y, Loganzo Jr F, Maslak P, et al. The mutation status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer 1995; 64(1): 37–46

    Article  PubMed  CAS  Google Scholar 

  47. Lenz HJ, Leichman CG, Danenberg KD, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996; 14(1): 176–82

    PubMed  CAS  Google Scholar 

  48. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1mRNA levels compement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16(1): 309–16

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Pennsylvania Cancer Center, 16 Penn Tower, 3400 Spruce Street, Philadelphia, Pennsylvania, 19104, USA

    Weijing Sun &  Daniel G. Haller

Authors
  1. Weijing Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel G. Haller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sun, W., Haller, D.G. Recent Advances in the Treatment of Gastric Cancer. Drugs 61, 1545–1551 (2001). https://doi.org/10.2165/00003495-200161110-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200161110-00002

Keywords

Search

Navigation